Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARCT Arcturus Therapeutics Ltd.

Trading 04-23 15:44:44 EDT

12.83

+0.66

+5.42%

High13.63	Low12.64	Vol348.16K
Open12.64	D1 Closing12.17	Amplitude8.13%
Mkt Cap347.95M	Tradable Cap318.63M	Total Shares27.12M
T/O4.55M	T/O Rate1.40%	Tradable Shares24.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ARCT","market":"US","secType":"STK","nameCN":"Arcturus Therapeutics Ltd.","latestPrice":12.83,"timestamp":1745437476337,"preClose":12.17,"halted":0,"volume":348159,"delay":0,"floatShares":24834573,"shares":27119823,"eps":-3,"marketStatus":"Trading","change":0.66,"latestTime":"04-23 15:44:44 EDT","open":12.64,"high":13.63,"low":12.64,"amount":4552443.52584,"amplitude":0.081348,"askPrice":12.84,"askSize":200,"bidPrice":12.82,"bidSize":196,"shortable":3,"etf":0,"ttmEps":-3,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745438400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":12.17,"preHourTrading":{"tag":"盘前","latestPrice":12.64,"preClose":12.17,"latestTime":"09:29 EDT","volume":138,"amount":1743.8501099999999,"timestamp":1745414999999},"postHourTrading":{"tag":"盘后","latestPrice":12.28,"preClose":12.17,"latestTime":"19:16 EDT","volume":12617,"amount":153546.4675,"timestamp":1745363816446},"volumeRatio":0.837916,"impliedVol":0.9609,"impliedVolPercentile":0.836},"requestUrl":"/m/hq/s/ARCT/wiki","defaultTab":"wiki","newsList":[{"id":"2529551471","title":"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529551471","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529551471?lang=en_us&edition=full_marsco","pubTime":"2025-04-23 04:01","pubTimestamp":1745352060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA2F7M9B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2529552535","title":"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529552535","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529552535?lang=en_us&edition=full_marsco","pubTime":"2025-04-23 04:01","pubTimestamp":1745352060,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 22, 2025----Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025.Arcturus Therapeutics First Quarter 2025 Earnings Conference Call. Arcturus TherapeuticsPublic Relations & Investor RelationsNeda SafarzadehVP, Head of IR/PR/Marketing 900-2682IR@ArcturusRx.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-report-first-quarter-200100429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","BK4007","CF","BK4585","RNA","BK4139","BK4588","ARCT","BK4093","LENZ"],"gpt_icon":0},{"id":"2528771893","title":"Arcturus Therapeutics (ARCT) Gets a Hold from Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2528771893","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528771893?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 19:15","pubTimestamp":1744888538,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Lili (Aurélie) Nsongo from Leerink Partners maintained a Hold rating on Arcturus Therapeutics (ARCT – Research Repo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/arcturus-therapeutics-arct-gets-a-hold-from-leerink-partners?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/arcturus-therapeutics-arct-gets-a-hold-from-leerink-partners?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2526619751","title":"High Growth Tech Stocks To Watch In The US April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526619751","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526619751?lang=en_us&edition=full_marsco","pubTime":"2025-04-12 01:38","pubTimestamp":1744393102,"startTime":"0","endTime":"0","summary":"As the U.S. market navigates a turbulent landscape marked by volatile trading sessions and fluctuating economic indicators, investors are closely watching the impact of ongoing tariff developments and bank earnings on major indices like the Dow Jones Industrial Average, which recently experienced significant swings. In such an environment, identifying high-growth tech stocks requires careful consideration of their resilience to macroeconomic pressures and potential for innovation amidst shifting trade policies.Top 10 High Growth Tech Companies In The United States. Click here to see the full list of 231 stocks from our US High Growth Tech and AI Stocks screener.Overview: Arcturus Therapeutics Holdings Inc. focuses on developing vaccines for infectious diseases and products targeting liver and respiratory rare diseases, with a market cap of $266.32 million.NasdaqGM:ARCT Revenue and Expenses Breakdown as at Apr 2025. Operations: Bel Fuse Inc. generates revenue primarily through its three","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-173822215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BELFB","BELFA","ARCT","BK4023","DV","BK4139"],"gpt_icon":0},{"id":"2526233615","title":"Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2526233615","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526233615?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 23:49","pubTimestamp":1744386540,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA  vaccine candidate, ARCT-2304, for active immunization to protect against the influenza A H5N1 virus.The Fast Track designation from the FDA facilitates rapid development and expedites the review of vaccines that are being developed to treat serious conditions and have the potential to address unmet medical needs.The Fast Track tag is likely to expedite the development path for ARCT-2304 and help in faster regulatory filing for the vaccine in the United States.In November 2024, the FDA cleared the investigational new drug  application to begin clinical studies on the sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza disease caused by the H5N1 virus.Arcturus developed the first sa-mRNA COVID-19 vaccine, Kostaive. The company has a collaboration agreement with renowned vaccine company CSL Seqirus for making innovative m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-gets-fdas-fast-track-154900033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","BK4139","CF","BK4548","LU0109394709.USD","BNTX","IE00BN0W2W23.USD","BK4532","BK4585","ADMA","LU0889565916.HKD","BK4093","JAZZ","IE00BN0W2V16.EUR","LU0823416689.USD","KRYS","FAST","ARCT","BK4007","BK4588","LU0320765992.SGD","BK4551","BK4533","IE00BN0W2T93.GBP","BK4568"],"gpt_icon":0},{"id":"2526511352","title":"Arcturus Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2526511352","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526511352?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 00:58","pubTimestamp":1744304280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARCT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2025 12:58 ET (16:58 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ARCT"],"gpt_icon":0},{"id":"2526569190","title":"Arcturus Gets FDA Fast-Track Designation for Pandemic Influenza A H5N1 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2526569190","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526569190?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 20:44","pubTimestamp":1744289040,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.Arcturus on Thursday said the designation recognizes the potential of ARCT-2304, a messenger RNA-based vaccine candidate, to address unmet medical needs for the prevention of disease caused by pandemic influenza A virus H5N1.The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.Arcturus, a San Diego medicines and vaccines company, in November launched a Phase 1 clinical study, supported in whole with federal funds from the Department of Health and Human Services.Outbreaks of avian influenza A H5N1, also known as bird flu, have been decimating U.S. poultry flocks since 2022, and while the federal government currently assesses the risk from H5N1 viruses to the general U.S. population as low, it has committed ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BYQQ9H92.USD","IE00BFXG0V08.USD","BK4588","BK4104","FAST","ARCT","BK4585","BK4567","IE00B5TLWC47.USD"],"gpt_icon":1},{"id":"2526569384","title":"Arcturus Therapeutics granted fast track designation for ARCT-2304 from FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2526569384","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526569384?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 20:31","pubTimestamp":1744288276,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics (ARCT) announced that the FDA has granted fast track designation for the self-amplifying mRNA vaccine candidate, ARCT-2304, d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-granted-fast-track-designation-for-arct-2304-from-fda?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-granted-fast-track-designation-for-arct-2304-from-fda?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2526563875","title":"Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1","url":"https://stock-news.laohu8.com/highlight/detail?id=2526563875","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526563875?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 20:00","pubTimestamp":1744286400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 10, 2025----Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration  has granted Fast Track Designation for the self-amplifying mRNA  vaccine candidate, ARCT-2304, designed for active immunization to protect against disease caused by influenza A H5N1 subtype contained in the vaccine. This designation recognizes the potential of ARCT-2304 as an innovative approach to address unmet medical needs for the prevention of disease caused by pandemic influenza A virus H5N1, a significant global health risk. The Phase 1 clinical study initiated in November 2024.\"We are pleased to receive Fast Track Designation from the FDA for ARCT-2304,\" said Joseph Payne, President and CEO of Arcturus Therapeutics. \"We remain steadfast in our commitment to the U.S. government to develop safe ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-receives-u-fda-120000445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","CF","ARCT","IE00BFXG0V08.USD","BK4141","NA","BK4567","IE00B5TLWC47.USD","IE00BYQQ9H92.USD","BK4505","RNA","BK4588","BK4139","FAST","BK4093","BK4104"],"gpt_icon":0},{"id":"2518080720","title":"Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=2518080720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518080720?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 11:35","pubTimestamp":1741750514,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics ($ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst expectations. Their annual reven...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/despite-revenue-setback-arcturus-therapeutics-arct-vaccine-breakthroughs-fuel-optimism?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/despite-revenue-setback-arcturus-therapeutics-arct-vaccine-breakthroughs-fuel-optimism?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARCT"],"gpt_icon":0},{"id":"2518275020","title":"Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2518275020","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518275020?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 22:50","pubTimestamp":1741618200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARCT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 10:50 ET (14:50 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","LENZ"],"gpt_icon":0},{"id":"2518230558","title":"Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Halozyme (HALO) and Arcturus Therapeutics (ARCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518230558","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518230558?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 08:21","pubTimestamp":1741566079,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Protagonist Therapeutics (PTGX – Research Report), H...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-protagonist-therapeutics-ptgx-halozyme-halo-and-arcturus-therapeutics-arct?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-protagonist-therapeutics-ptgx-halozyme-halo-and-arcturus-therapeutics-arct?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0053671581.USD","BK4137","HCSG","ARCT","BK4139","HALO","PTGX"],"gpt_icon":0},{"id":"2518786283","title":"Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2518786283","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518786283?lang=en_us&edition=full_marsco","pubTime":"2025-03-09 21:31","pubTimestamp":1741527083,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc.  missed earnings with its latest annual results, disappointing overly-optimistic forecasters. Unfortunately, Arcturus Therapeutics Holdings delivered a serious earnings miss. Revenues of US$152m were 13% below expectations, and statutory losses ballooned 27% to US$3.00 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.See our latest analysis for Arcturus Therapeutics Holdings. The most important thing to note is the forecast of increased losses next year, suggest","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-holdings-inc-nasdaq-133123566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","USAW.SI","NVIW.SI","NQmain","BK4139","ARCT","QID","MNQmain","LU2210149790.SGD","BK4112","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","PSQ","IE00BKPKM429.USD","NDAQ",".IXIC","USJW.SI","SQQQ","TSYW.SI","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","TQQQ"],"gpt_icon":1},{"id":"2517459163","title":"Arcturus Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517459163","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517459163?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 01:44","pubTimestamp":1741369440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARCT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 12:44 ET (17:44 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","LENZ"],"gpt_icon":0},{"id":"2517345814","title":"Q4 2024 Arcturus Therapeutics Holdings Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2517345814","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517345814?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 00:16","pubTimestamp":1741364177,"startTime":"0","endTime":"0","summary":"Neda Safarzadeh; Vice President and Head of Investor Relations, Public Relations, and Marketing; Arcturus Therapeutics Holdings Inc. Joseph Payne; President, Chief Executive Officer, Director; Arcturus Therapeutics Holdings Inc. Andrew Sassine; Chief Financial Officer, Director; Arcturus Therapeutics Holdings Inc. Padmanabh Chivukula; Chief Operating Officer, Chief Scientific Officer; Arcturus Therapeutics Holdings Inc. Thank you for holding, ladies and gentlemen. We thank you for your patience and ask that you please continue to hold. Good day, everyone, and welcome to Arcturus Therapeutics fourth and full-year 2024 earnings call.  Please note, today's call will be recorded  It is now my pleasure to turn the conference over to Neda Safarzadeh, Vice President and Head of Investor Relations, Public Relations, and Marketing. Neda, please go ahead.Thank you, Neda. It's good to be with you again, everybody. We look forward to providing our updates today on our quarterly investor call. I wi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-arcturus-therapeutics-holdings-161617041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","ARCT"],"gpt_icon":0},{"id":"2517362594","title":"Arcturus Therapeutics Holdings Inc : Canaccord Genuity Cuts Target Price to $68 From $74","url":"https://stock-news.laohu8.com/highlight/detail?id=2517362594","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517362594?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 22:23","pubTimestamp":1741357404,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ12A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2517171608","title":"Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2517171608","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517171608?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 15:17","pubTimestamp":1741331836,"startTime":"0","endTime":"0","summary":"Revenue : $152.3 million, a decrease from $166.8 million in 2023.Revenue : $22.8 million, down from $30.9 million in Q4 2023.Net Loss : Approximately $80.9 million or $3 per diluted share.Total Operating Expenses : $56.2 million, compared to $49.1 million in Q4 2023.Research and Development Expenses : $43.8 million, up from $36.6 million in Q4 2023.General and Administrative Expenses : $52.8 million, slightly down from $52.9 million in 2023.Cash and Cash Equivalents : $293.9 million, down from $348.9 million at the end of 2023.Cash Burn : Approximately $55 million, compared to $45 million in 2023.Gross Profit from KOSTAIVE Sales : Approximately $28 million.GuruFocus has detected 4 Warning Signs with ARCT.Arcturus Therapeutics Holdings Inc  received European Commission approval for KOSTAIVE, the world's first approved self-amplifying mRNA COVID-19 vaccine.Arcturus Therapeutics Holdings Inc  achieved a total of approximately $473.1 million in upfront payments and milestones from CSL as o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-holdings-inc-arct-071716440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARCT"],"gpt_icon":0},{"id":"2517178708","title":"U.S. RESEARCH ROUNDUP- Adobe, Tesla, Victoria's Secret","url":"https://stock-news.laohu8.com/highlight/detail?id=2517178708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517178708?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 15:04","pubTimestamp":1741331083,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Adobe, Tesla, Victoria's Secret March 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Te","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nL3N3PQ0LA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSYW.SI","BJ","LU0889566641.SGD","LU1035775433.USD","LU0820561818.USD","GM","BK4596","GT","LU0170899867.USD","LU0162691827.USD","MLNK","LU2095319765.USD","BURL","BK4539","STZ","LU0345769631.USD","LU0198837287.USD","HRZN","LU0234570918.USD","LU0321505868.SGD","LU1815333072.USD","ADBE","BK4119","LU0477156953.USD","ARCT","PRTH","LU0072461881.USD","LU0234572021.USD","LU0985481810.HKD","LU1496350502.SGD","SG9999003800.SGD","SGXZ81514606.USD","RYN","W","SG9999002232.USD","LU2210149790.SGD","GMS","OLLI","LU0456855351.SGD","LU0106261372.USD","LU2063271972.USD","COOK","VSCO","LU0792757196.USD","TSLA","F","LU2108987350.USD"],"gpt_icon":1},{"id":"2517012336","title":"Arcturus Therapeutics Holdings Inc : Leerink Partners Cuts Target Price to $65 From $70","url":"https://stock-news.laohu8.com/highlight/detail?id=2517012336","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517012336?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 11:53","pubTimestamp":1741319612,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PP1CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2517694143","title":"Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517694143","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517694143?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 06:15","pubTimestamp":1741299304,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics  came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -226.47%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.70 per share when it actually produced a loss of $0.26, delivering a surprise of 62.86%.Arcturus Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $22.77 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 60.60%. This compares to year-ago revenues of $33.99 million. The company has topped consensus revenue estimates two times over the last four quarters.Arcturus Therapeutics shares have lost about 5.4% since the beginning of the year versus the S&P 500's decline of -0.7%.While Arcturus Therapeutics has underperformed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-arct-reports-q4-221504874.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARCT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcturusrx.com","stockEarnings":[{"period":"1week","weight":0.1514},{"period":"1month","weight":-0.0551},{"period":"3month","weight":-0.273},{"period":"6month","weight":-0.3595},{"period":"1year","weight":-0.5503},{"period":"ytd","weight":-0.2829}],"compareEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.0898},{"period":"1year","weight":0.0551},{"period":"ytd","weight":-0.1004}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.073454},{"month":2,"riseRate":0.5,"avgChangeRate":0.009833},{"month":3,"riseRate":0.25,"avgChangeRate":-0.05017},{"month":4,"riseRate":0.583333,"avgChangeRate":0.105779},{"month":5,"riseRate":0.636364,"avgChangeRate":0.1056},{"month":6,"riseRate":0.583333,"avgChangeRate":0.023074},{"month":7,"riseRate":0.583333,"avgChangeRate":0.109538},{"month":8,"riseRate":0.5,"avgChangeRate":0.045801},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.063785},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.046065},{"month":11,"riseRate":0.666667,"avgChangeRate":0.063018},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.062042}],"exchange":"NASDAQ","name":"Arcturus Therapeutics Ltd.","nameEN":"Arcturus Therapeutics Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcturus Therapeutics Ltd.,ARCT,Arcturus Therapeutics Ltd.股票,Arcturus Therapeutics Ltd.股票老虎,Arcturus Therapeutics Ltd.股票老虎国际,Arcturus Therapeutics Ltd.行情,Arcturus Therapeutics Ltd.股票行情,Arcturus Therapeutics Ltd.股价,Arcturus Therapeutics Ltd.股市,Arcturus Therapeutics Ltd.股票价格,Arcturus Therapeutics Ltd.股票交易,Arcturus Therapeutics Ltd.股票购买,Arcturus Therapeutics Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}